Navigation Links
Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
Date:10/1/2009

NEW YORK, Oct. 1 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid X receptor (FXR) agonist INT-747 has met the primary endpoint of improved insulin sensitization in a 6 week double blind, placebo controlled trial in type 2 diabetic patients with nonalcoholic fatty liver disease (NAFLD).

By employing a euglycemic insulin clamp procedure, the study demonstrated that a single oral daily dose of INT-747 statistically significantly improved glucose disposal rate, consistent with improved hepatic and peripheral insulin sensitivity. Furthermore, patients treated with INT-747 demonstrated statistically significant weight loss and improved biochemical markers of liver function. The compound was well tolerated at the doses tested, with side effects similar to placebo.

Intercept's Chief Medical Officer, David Shapiro, MD, commented, "INT-747 therapy generated several clinically meaningful signals in this first proof of concept study, validating the mechanism of action of FXR activation that we and other groups have described preclinically." Dr. Shapiro is presenting the results of the trial on Friday, Oct. 2, in a plenary session at the European Association for the Study of Diabetes (EASD) annual meeting.

Insulin resistance is an important driver of liver fibrosis, the progressive scarring that can lead to cirrhosis. Based on INT-747's ability to improve insulin sensitivity and other important parameters of liver function in this patient population, Intercept is planning to initiate a Phase II trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. There are an estimated 5 million or more NASH patients in the United States alone with no effective therapeutics currently available.

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chr
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
4. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
5. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
6. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
7. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
8. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... FORT WORTH, Texas , December 18, 2014 ... is a networked software application/module that is used ... and related images. RIS comprises a patient tracking ... tracking system. The integration of RIS with HIS ... is used for patient registration and patient scheduling, ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3
... reduce the use of mechanical ventilation with premature infants in ... affect those children,s outcomes while reducing the cost of care, ... The team, led by Bernadette Levesque, MD, ... and the Neonatal Intensive Care Unit (NICU) at St. Elizabeth,s ...
... SPRING, Md., June 10, 2011 The U.S. Food ... Merck,s redesigned drug container labels that include a new ... on product and strength differentiation. (Logo: ... the revision of 34 container labels for 16 solid ...
Cached Medicine Technology:Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3FDA Approves Redesigned Labels for Some Merck Drugs 2
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Eufaula, Oklahoma, ... to Lake Eufaula, the state’s largest lake with more ... town is home to a little more than 3,000 ... P.M. on Saturday, the 6th of December. , Featuring ... way through downtown Eufaula on Main Street. Narconon ...
(Date:12/19/2014)... The print component of Vision and ... of the Toronto Star, with a circulation of approximately ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... publication features an exclusive interview with Mark DeMontis ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Potentially illness-causing ... herbs bought at farmers markets, according to a new ... almost 50 vendors from 13 farmers markets in Los ... Seattle area. Out of almost 150 samples tested, 24 ... positive for salmonella, according to the researchers. Both ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... ... best hospitals in the United States by U.S. News & World Report. , ... New York, NY (Vocus) July 16, 2009 -- The Mount Sinai Medical ... States by U.S. News & World Report. , , ,In the 2009-10 America,s Best Hospital issue, Mount ...
... , BOCA RATON, Fla., July 16 JAG ... further update of the status of its acquisition of CardioGenics ... closing date for the acquisition, currently scheduled for a date ... a date on or before July 24, 2009 to allow ...
... ... their practices and prepare for the future just launched on Monday. , ... (Vocus) July 16, 2009 -- The ... 25 years of combined experience in dental practice sales and appraisals, is the first membership-based, ...
... , , WASHINGTON, July 16 ... committees crafting the House version of a health care reform bill ... those revenues to a special fund to finance prevention and wellness ... taxes are an important tool in reducing the public health toll ...
... to higher risk of heart attack, stroke, agency says, ... Food and Drug Administration has begun a safety review ... an increased risk of heart attack, abnormal heart rhythm, ... Early results from the Evaluating the Clinical Effectiveness and ...
... , , , BEDFORD, Ohio, ... Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. ... by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO ...
Cached Medicine News:Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 2Health News:The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals 3Health News:JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc. 2Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:Raise Federal Alcohol Tax to Finance Prevention Trust Fund, Partnership Urges House Chairmen 2Health News:FDA Investigating Safety of Asthma Drug Xolair 2Health News:Bedford Laboratories(TM) to Begin Shipping Ceftriaxone for Injection USP 2
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: